OncoMatch/Clinical Trials/NCT06612944
Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation in Very High-Risk MDS Patients Based on IPSS-M Stratification
Is NCT06612944 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation for myelodysplastic syndromes, adult.
Treatment: Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation — By collecting interventional clinical data to assess the survival and relapse conditions of patients post-transplantation and comparing them with historical data, the primary study endpoint is the 1-year and 2-year relapse-free survival (RFS) post-transplantation. This includes the time from the start of treatment until the documentation of disease progression (bone marrow smear blast cells \> 5% or extramedullary relapse) or death due to any cause, whichever occurs first. This experiment aims to improve the post-transplant survival rates of MDS patients classified as very high risk under the IPSS-M stratification and to explore pathways to prevent relapse.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Myelodysplastic Syndrome
Disease stage
Required: Stage VERY HIGH-RISK BY IPSS-M SCORING (IPSS-M)
classified as very high-risk by IPSS-M scoring
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: hematopoietic stem cell transplantation
Lab requirements
Kidney function
serum creatinine ≤ 1.5× uln
Liver function
total bilirubin ≤ 1.5× uln; alt and ast ≤ 2.0× uln
Cardiac function
ejection fraction ≥ 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06612944 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior hematopoietic stem cell transplantation disqualifies patients from enrollment.
What disease stage is eligible?
Stage VERY HIGH-RISK BY IPSS-M SCORING is required.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages